Recombinant IL-2 given intra-splenically and intravenously in advanced malignant melanoma: a phase I/II study.
Thatcher
N
N
Christie Hospital & Paterson Institute of Cancer Research, Manchester, U.K.
Dazzi
H
H
Gosh
A
A
Johnson
R J
RJ
D000328:Adult; D000368:Aged; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007376:Interleukin-2 / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000556:secondary; D008875:Middle Aged; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects
D007376:Interleukin-2; D011994:Recombinant Proteins